Antibody-Based Cancer Biomarkers And Therapeutic Agents
Background:
The National Cancer Institute's Mammary Biology and Tumorigenesis
Laboratory is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize isoform-specifc antibodies to the human
prolactin receptor.
Technology:
Prolactin is a key hormone in normal breast development and plays a
role in the growth and development of other major organs such as
the prostate. The biologic function of prolactin is mediated by
specific receptors on the cell surface, with breast cancer cells
containing more receptors than normal tissue. The prolactin
receptor, a member of the large class-1 cytokine receptor
superfamily, has three major isoforms that are cell associated. The
specific isoform concentration and distribution determines
biological activity and may determine susceptibility to
antiprolactin drugs.
This technology describes several antibodies, both polyclonal and
monoclonal, to the prolactin receptor. These include antibodies to
the three major isoforms: the long isoform (LF), two short isoforms
(SF1a and SF1b), and the secreted form, prolactin receptor
7-11. These antibodies can be used for the diagnosis of
prolactin sensitive tumors as well as for the development of
targeted cancer therapeutics. Furthermore, the presence of
the secreted prolactin receptor 7-11 may provide a blood test for
prolactin responsive tumors.
Further R&D Needed:
- Screening of breast and prostate cancers by
immunohistochemistry for receptor isoforms
- Screening of serum from breast cancer patients
- Examine isoform profiles in normal, high-risk and cancer
patients
R&D Status: Pre-clinical
IP Status: Because this technology is a Research Tool, patent
protection is not being sought pursuant to NIH policy.
Value Proposition:
- Diagnostic tool for the detection of prolactin sensitive
tumors
- Development of conjugated antibodies used in targeted therapy
of cancer
- Use of antibodies as a serum diagnostic in high-throughput
assays
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement # 760
Revision: 2008-09-30
This opportunity is also listed under the following categories: